Guggenheim analyst Seamus Fernandez initiated coverage of Amylyx (AMLX) with a Buy rating and $17 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMLX:
- Amylyx initiated with a Buy at Citi
- Optimistic Buy Rating for Amylyx Pharmaceuticals’ AMX0114 Based on Promising ALS Treatment Mechanism and Trial Insights
- Amylyx Pharmaceuticals Inc Holds Annual Stockholder Meeting
- Amylyx receives fast track designation for AMX0114 from FDA
- Amylyx initiated with a Buy at TD Cowen